232 related articles for article (PubMed ID: 8058726)
1. Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities.
Sánchez-García I; Rabbitts TH
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7869-73. PubMed ID: 8058726
[TBL] [Abstract][Full Text] [Related]
2. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.
Zinszner H; Albalat R; Ron D
Genes Dev; 1994 Nov; 8(21):2513-26. PubMed ID: 7958914
[TBL] [Abstract][Full Text] [Related]
3. Positive and negative transcriptional control by the TAL1 helix-loop-helix protein.
Hsu HL; Wadman I; Tsan JT; Baer R
Proc Natl Acad Sci U S A; 1994 Jun; 91(13):5947-51. PubMed ID: 8016094
[TBL] [Abstract][Full Text] [Related]
4. Fusion of the EWS and CHOP genes in myxoid liposarcoma.
Panagopoulos I; Höglund M; Mertens F; Mandahl N; Mitelman F; Aman P
Oncogene; 1996 Feb; 12(3):489-94. PubMed ID: 8637704
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation.
Kanoe H; Nakayama T; Hosaka T; Murakami H; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Ron D; Sasaki MS; Toguchida J
Oncogene; 1999 Jan; 18(3):721-9. PubMed ID: 9989822
[TBL] [Abstract][Full Text] [Related]
6. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma.
Pérez-Losada J; Sánchez-Martín M; Rodríguez-García MA; Pérez-Mancera PA; Pintado B; Flores T; Battaner E; Sánchez-Garćia I
Oncogene; 2000 Dec; 19(52):6015-22. PubMed ID: 11146553
[TBL] [Abstract][Full Text] [Related]
7. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice.
Pérez-Losada J; Pintado B; Gutiérrez-Adán A; Flores T; Bañares-González B; del Campo JC; Martín-Martín JF; Battaner E; Sánchez-García I
Oncogene; 2000 May; 19(20):2413-22. PubMed ID: 10828883
[TBL] [Abstract][Full Text] [Related]
8. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma.
Crozat A; Aman P; Mandahl N; Ron D
Nature; 1993 Jun; 363(6430):640-4. PubMed ID: 8510758
[TBL] [Abstract][Full Text] [Related]
9. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma.
Rabbitts TH; Forster A; Larson R; Nathan P
Nat Genet; 1993 Jun; 4(2):175-80. PubMed ID: 7503811
[TBL] [Abstract][Full Text] [Related]
10. Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.
Kuroda M; Ishida T; Horiuchi H; Kida N; Uozaki H; Takeuchi H; Tsuji K; Imamura T; Mori S; Machinami R
Am J Pathol; 1995 Nov; 147(5):1221-7. PubMed ID: 7485386
[TBL] [Abstract][Full Text] [Related]
11. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.
Valge-Archer VE; Osada H; Warren AJ; Forster A; Li J; Baer R; Rabbitts TH
Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8617-21. PubMed ID: 8078932
[TBL] [Abstract][Full Text] [Related]
12. Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice.
Pérez-Mancera PA; Pérez-Losada J; Sánchez-Martín M; Rodríguez-García MA; Flores T; Battaner E; Gutiérrez-Adán A; Pintado B; Sánchez-García I
Oncogene; 2002 Mar; 21(11):1679-84. PubMed ID: 11896599
[TBL] [Abstract][Full Text] [Related]
13. FUS/TLS-CHOP chimeric transcripts in liposarcoma tissues.
Yang X; Nagasaki K; Egawa S; Maruyama K; Futami H; Tsukada T; Yokoyama R; Beppu Y; Fukuma H; Shimoda T
Jpn J Clin Oncol; 1995 Dec; 25(6):234-9. PubMed ID: 8523819
[TBL] [Abstract][Full Text] [Related]
14. Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia.
Panagopoulos I; Lassen C; Isaksson M; Mitelman F; Mandahl N; Aman P
Oncogene; 1997 Sep; 15(11):1357-62. PubMed ID: 9315104
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin stimulates transcription of the TAL1/SCL gene and phosphorylation of its protein products.
Prasad KS; Jordan JE; Koury MJ; Bondurant MC; Brandt SJ
J Biol Chem; 1995 May; 270(19):11603-11. PubMed ID: 7744799
[TBL] [Abstract][Full Text] [Related]
16. TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain.
Prasad DD; Ouchida M; Lee L; Rao VN; Reddy ES
Oncogene; 1994 Dec; 9(12):3717-29. PubMed ID: 7970732
[TBL] [Abstract][Full Text] [Related]
17. Helix-loop-helix (E2-5, HEB, TAL1 and Id1) protein interaction with the TCRalphadelta enhancers.
Bernard M; Delabesse E; Smit L; Millien C; Kirsch IR; Strominger JL; Macintyre EA
Int Immunol; 1998 Oct; 10(10):1539-49. PubMed ID: 9796921
[TBL] [Abstract][Full Text] [Related]
18. A novel FUS/CHOP chimera in myxoid liposarcoma.
Panagopoulos I; Mertens F; Isaksson M; Mandahl N
Biochem Biophys Res Commun; 2000 Dec; 279(3):838-45. PubMed ID: 11162437
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL.
Ono Y; Fukuhara N; Yoshie O
J Biol Chem; 1997 Feb; 272(7):4576-81. PubMed ID: 9020185
[TBL] [Abstract][Full Text] [Related]
20. Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21).
Panagopoulos I; Mandahl N; Mitelman F; Aman P
Oncogene; 1995 Sep; 11(6):1133-7. PubMed ID: 7566973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
